CBSC (Cardiac Biotech Solutions) Deferred Tax: $0.00 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiac Biotech Solutions Deferred Tax?

Cardiac Biotech Solutions CBSC +10.13% Deferred Tax is $0.00 Mil as of Jun. 2025.

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Cardiac Biotech Solutions's change in deferred tax for the three months ended in Jun. 2025 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2025 was $0.00 Mil.

Cardiac Biotech Solutions Deferred Tax Related Terms

Cardiac Biotech Solutions Deferred Tax Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions Deferred Tax Chart

Cardiac Biotech Solutions Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Deferred Tax
0.00 0.00 0.00 0.00 0.00

Cardiac Biotech Solutions Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cardiac Biotech Solutions Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Deferred Tax →
What does a Deferred Tax of $0.00 Mil mean?
Cardiac Biotech Solutions (CBSC) has a Deferred Tax of $0.00 Mil as of Jun. 2025. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for Cardiac Biotech Solutions.
Is Cardiac Biotech Solutions' Deferred Tax too high?
Cardiac Biotech Solutions' current Deferred Tax is $0.00 Mil.
How does Cardiac Biotech Solutions' Deferred Tax compare to LUCY and NXGL?
Cardiac Biotech Solutions' Deferred Tax of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Deferred Tax for a Medical Devices & Instruments company?
A good Deferred Tax depends on the Medical Devices & Instruments industry context. However, Deferred Tax should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Deferred Tax mean?
A high Deferred Tax can signal that a stock is expensive relative to its fundamentals. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for Cardiac Biotech Solutions. Cardiac Biotech Solutions's current Deferred Tax is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current Deferred Tax of $0.00 Mil. The current Deferred Tax is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Deferred Tax calculated?
Deferred Tax is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Deferred Tax is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.